阿帕替尼联合卡瑞利珠单抗治疗晚期肝癌的临床效果及安全性观察

Clinical Efficacy and Safety Observation of Apatinib Combined with Carolizumab in the Treatment of Advanced Liver Cancer

目的:探讨阿帕替尼联合卡瑞利珠单抗治疗晚期肝癌的临床疗效及安全性。方法:选取2020年3月—2023年3月南通市通州区人民医院收治的60例确诊为肝细胞癌(HCC)晚期的患者作为研究对象。采取随机数表法将其分为研究组和对照组,每组各30例。研究组与对照组分别给予卡瑞利珠单抗联合甲阿帕替尼治疗、阿帕替尼单药治疗,针对治疗后两组的不良反应、临床疗效以及疾病无进展生存时间(DFS)进行比较研究。结果:研究组治疗6周后疾病缓解率(ORR)和疾病控制率(DCR)均高于对照组,差异有统计学意义(P<0.05);治疗后,两组各项不良反应比较,差异无统计学意义(P>0.05);对照组的中位DFS为4.2个月,研究组中位DFS为6.8个月;研究组的中位DFS高于对照组,差异有统计学意义(P<0.05)。结论:阿帕替尼联合卡瑞利珠单抗相对单一阿帕替尼用药具有更好的近期临床疗效,患者的生存期获益更大,且并不会增加用药后的不良反应。

Objective:To explore the clinical efficacy and safety of Apatinib combined with Carolizumab in the treatment of advanced liver cancer.Method:Sixty patients diagnosed with advanced hepatocellular carcinoma(HCC)admitted to Tongzhou District People's Hospital of Nantong City from March 2020 to March 2023 were selected as the study objects.The patients were divided into study group and control group,with 30 cases in each group.For the study group and the control group,Carolizumab combined with Apatinib treatment and apatinib monotherapy treatment were respectively given,and the adverse reactions,clinical efficacy and progression-free survival time of the two groups after treatment were compared.Result:After 6 weeks of treatment,the ORR and DCR of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).The median DFS in the control group was 4.2 months,while the median DFS in the study group was 6.8 months.The median DFS of the study group was higher than that of control group,with a statistical significance(P<0.05).Conclusion:The combination of Apatinib and Carolizumab has better short-term clinical efficacy compared to the single use of Apatinib,with greater survival benefits for patients and no increase in adverse reactions after medication.